TTE Improves Clinical Management of Stable Chest Pain (TICM-SCP)

July 15, 2025 updated by: Zhou Jia, Tianjin Chest Hospital

Improving the Clinical Management of Stable Chest Pain Based on Imaging: a Registry of Transthorcic Echocardiography

The investigator aims to prospectively enroll patients who were referred for transthorcic echocardiography (TTE) for the assessment of stable chest pain (SCP) suspected of obstructive coronary artery disease (CAD). All patients underwent TTE according to established guidelines and local institutional protocols. This study will determine if TTE-based imaging evaluation can provide more informaton to improve clinical management for SCP, including fewer MACE and better decision-making of downstream investigations and therapeutic interventions.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

50000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • China
      • Tianjin, China
        • Recruiting
        • Tianjin Chest Hospital
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients who were referred for TTE for the assessment of SCP suspected of CAD.

Description

Inclusion Criteria:

  • symptomatic patients with SCP suspected of obstructive CAD.
  • referred for TTE for the assessment of SCP.
  • ≥18 years of age.
  • signed informed consent.

Exclusion Criteria:

  • acute coronary syndromes
  • previous CAD or coronary revascularization
  • nonsinus rhythm
  • cardiomyopathy, valvular disease, congenital heart disease or left cardiac insufficiency because of other reasons

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
TTE
Diagnostic test: TTE
All patients underwent TTE according to established guidelines and local institutional protocols. The imaging data were evaluated using different image post-processing software to comprehensively analyse anatomical, functional and histological information of coronary.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Major adverse cardiovascular events
Time Frame: 10 years
10 years

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Invasive coronary angiography
Time Frame: 10 years
Invasive coronary angiography occurred at follow-up after TTE, attributed to TTE results or unplanned.
10 years
Medication prescription
Time Frame: 10 years
Change for medication prescription of antiplatelet agents, anti-ischemic drugs, lipid-lowering agents, angiotensin-converting enzyme inhibition and so on, attributed to TTE results or unplanned,
10 years
Coronary revascularization
Time Frame: 10 years
PTCA, PCI or CABG occurred at follow-up after TTE, attributed to TTE results or unplanned.
10 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Tianjin Chest Hospital

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2025

Primary Completion (Estimated)

December 31, 2030

Study Completion (Estimated)

December 31, 2040

Study Registration Dates

First Submitted

July 3, 2025

First Submitted That Met QC Criteria

July 3, 2025

First Posted (Actual)

July 14, 2025

Study Record Updates

Last Update Posted (Actual)

July 18, 2025

Last Update Submitted That Met QC Criteria

July 15, 2025

Last Verified

July 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 2025KY-019-01

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Coronary Artery Disease

Clinical Trials on TTE

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Congo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe